Crystalys Therapeutics
Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout
$130MSeries B
Role not disclosedLoading investors…
Activity from announced rounds
Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout